CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm. Th...
CTS received notification from Sanochemia Pharmazeutika AG of their intent to immediately discontinu...
CTS originally communicated that Tampa will convert from the current Grifols Ultrio Plus NAT triplex...
On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...
IPFA welcomes Marion Lanteri as Executive Board member, CTS as new member organization
Celebrate National Blood Donor Month throughout January by inviting eligible individuals to donate b...